Laboratorios Farmaceuticos Rovi has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Laboratorios Farmaceuticos Rovi SA shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Laboratorios Farmaceuticos Rovi's Interest Coverage for the quarter that ended in Mar. 2026 was 15.46.
Laboratorios Farmaceuticos Rovi's debt to revenue ratio for the quarter that ended in Mar. 2026 was 0.19.
As of today, Laboratorios Farmaceuticos Rovi's Altman Z-Score is 10.01.
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Laboratorios Farmaceuticos Rovi has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.
Laboratorios Farmaceuticos Rovi Financial Strength Related Terms
LABFF vs ZTS, UTHR, VTRS: Financial Strength Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Financial Strength vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Financial Strength distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Laboratorios Farmaceuticos Rovi has a Z-score of 10.01, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 10.01 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (LABFF) has a Financial Strength of 10 as of Mar. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 11% above median its historical median of 9.00. Over the past decade, Laboratorios Farmaceuticos Rovi's Financial Strength has ranged from 8.00 to 10.00.
Is Laboratorios Farmaceuticos Rovi's Financial Strength too high?
Laboratorios Farmaceuticos Rovi's current Financial Strength of 10 is 11% above median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 8.00 to a high of 10.00. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Financial Strength compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Financial Strength of 10 can be compared against companies in the Drug Manufacturers industry. Historically, Laboratorios Farmaceuticos Rovi's own Financial Strength has ranged from 8.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Drug Manufacturers company?
A good Financial Strength depends on the Drug Manufacturers industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Financial Strength is 10, which is 11% above median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Financial Strength of 10. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current Financial Strength is 10, which is 11% above median its 10-year median of 9.00. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Financial Strength is 10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.
Key valuation signals for LABFF:
Financial Strength: 10 (11% above median its 10-year median of 9.00)
GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score
Get the complete analysis for LABFF
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 